Mark Wakefield, MD
Urology · Columbia, MONPI 1649226291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Boston Scientific at 39.2% of the total. 2025 is the largest year on record at $1,747, 5.2 times the $333 reported in 2019.
Across 138 payments — averaging $42.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$714
- Coloplast$288
- Convatec Inc.$285
- Urogen Pharma, Inc.$235
- Endo USA, Inc.$233
- plus $2K from 25 others
Across 12 payments — averaging $9670.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$114K
- Merck$2K
What the payments were for
- Food & beverage$5,57695%
- Education$2985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 40 | $2,301 |
| Medtronic(2 entities) | 10 | $714 |
| Coloplast | 5 | $288 |
| Convatec Inc. | 12 | $285 |
| Urogen Pharma, Inc. | 7 | $235 |
| Endo USA, Inc. | 7 | $233 |
| Merck | 6 | $191 |
| Astellas Pharma US Inc | 3 | $184 |
| Histosonics, Inc. | 1 | $150 |
| Endo Pharmaceuticals Inc. | 7 | $141 |
| Johnson & Johnson(3 entities) | 7 | $133 |
| Medical Device Business Services, Inc. | 1 | $108 |
| Teleflex LLC | 3 | $106 |
| Cook Medical LLC | 1 | $100 |
| Olympus America Inc. | 3 | $94 |
| Ferring Pharmaceuticals Inc. | 3 | $86 |
| Stryker | 1 | $76 |
| ABC Home Medical Supply, Inc. | 4 | $64 |
| 180 Medical, Inc. | 3 | $53 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $49 |
| Procept Biorobotics Corporation | 1 | $36 |
| AbbVie(2 entities) | 2 | $33 |
| KARL Storz Endoscopy-america | 2 | $33 |
| Laborie Medical Technologies Corp. | 1 | $27 |
| Axonics, Inc. | 1 | $27 |
| Edwards Lifesciences | 1 | $24 |
| Vertex | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Siemens Medical Solutions USA, Inc. | 1 | $23 |
| Tolmar, Inc. | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LithoVue$525
- INTERSTIM$399
- rezum Generator$228
- AMS 700 CXR RTE KIT$214
- GENERAL ERECTILE DYSFUNCTION$134
- TITAN$121
How this compares
$5,874 in reported general payments places this provider in the 60th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $388,599 |
| MyrbetriqMirabegron | 109 | $53,768 |
| GemtesaVibegron | 25 | $23,564 |
| Testosterone | 24 | $6,983 |
| Tamsulosin Hcl | 336 | $6,024 |
| Methenamine Hippurate | 62 | $3,992 |
| Finasteride | 260 | $3,980 |
| Potassium Citrate ErPotassium Citrate | 18 | $3,190 |
| Silodosin | 17 | $2,376 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 72 | $2,181 |
| Trospium Chloride | 24 | $2,122 |
| Cefpodoxime Proxetil | 19 | $1,780 |
| Solifenacin Succinate | 39 | $1,686 |
| Oxybutynin Chloride | 73 | $1,633 |
| Bethanechol Chloride | 24 | $1,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $184 | $442,367130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 urology providers in Missouri.
Other urology in Columbia
- Jack CampbellColumbia$54K
- Julie RileyColumbia$10K
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Samuel KuykendallKansas City$141K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
- Majdee IslamSaint Peters$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.